Duality Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Duality Advisers’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-67,810	Closed	-$1.73M	–	729
2021 Q3	$1.73M	Buy	67,810 +16,051	+31%	+$472K	0.13%	269
2021 Q2	$1.81M	Buy	+51,759	New	+$2.02M	0.16%	216
2020 Q4	–	Sell	-71,610	Closed	-$3.95M	–	771
2020 Q3	$3.95M	Buy	+71,610	New	+$4.55M	0.25%	91

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Duality Advisers's GBT Position: Q4 2021 in Review

Duality Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 67,810 shares — an estimated $1.73M sold.

Duality Advisers first reported a position in GBT in Q3 2020 and held it in 3 quarters. The position peaked at $3.95M in Q3 2020. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

Duality Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Duality Advisers sold 67,810 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $1.73M.
Duality Advisers first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 3 quarters.
Duality Advisers's Global Blood Therapeutics, Inc. position peaked at $3.95M in Q3 2020.
206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.